Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

Gastric Cancer Clinical Trial

Official title:

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Her-2 Negative Unresectable Locally Advanced Gastric Cancer: a National Multicenter Randomized Controlled Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05914610
• Other study ID #: FUGES-028
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: September 1, 2023
• Est. completion date: July 30, 2028

Study information

• Verified date: August 2023
• Source: Fujian Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: July 30, 2028
• Est. primary completion date: July 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age: 18-75 years of age;

2. Pathological (including histological or cytological) confirmation of gastric adenocarcinoma;

3. Before surgery, CT/MRI, PET-CT, if necessary, laparoscopic exploration to determine the clinical stage of T4bN0M0 and TanyN2-3M0, and determined by researchers that the local advanced patients can not be resectable;

4. At least one measurable detected by CT examination in accordance with the RECIST1.1

5. ECOG#Eastern Cooperative Oncology Group#PS#Performance Status#:0-1 scores;

6. The expected survival time is more than 3 months

7. The main organ function is normal, which should meet the following criteria:

#1#blood routine examination standards should be met#no blood transfusion within 14 days#

a.HB= 100g/L b. WBC=3×109/L c. ANC=1.5×109/L d. PLT=100×109/L #2#biochemical examination shall comply with the following criteria#

1. BIL#1.5 normal upper limit ULN

2. ALT and AST#2.5 ULN

3. Cr=1 ULN#CCR#creatinine clearance rate##60ml/min(Cockcroft Gault formula)

8. Women of childbearing age must have a pregnancy test in 7 days before entering the group (in serum), and the results were negative, and willing to use appropriate contraception during the study period and the last 8 weeks after giving drug test; men should have the surgical sterilization, or adopt the appropriate contraceptive methods during the test and the last 8 weeks after giving drug test#

9. No other clinical studies were conducted before and during the treatment

10. Participants is willing to participate in this study, sign the informed consent, have good compliance, cooperate with follow-up

Exclusion Criteria:

1. Imaging or intraoperative exploration found patients with peritoneum, liver, lung and other distant metastases

2. Patients with allergies or suspected allergies to study drugs or similar drugs

3. Confirmed HER-2 positive patients

4. Other malignancies in the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix

5. Live vaccine was administered within 4 weeks prior to enrolling or possibly during the study period

6. Had an active autoimmune disease or a history of autoimmune disease within 4 weeks prior to enrollment

7. Past recipients of allogeneic bone marrow transplants or organ transplants

8. Patient has any current disease or condition that affects drug absorption, or the patient is unable to take the drug orally

9. The blood pressure of patients with hypertension cannot be reduced to the normal range by the one antihypertensive drugs (systolic pressure =150 mmHg, diastolic pressure =100 mmHg) or hard to controled by two or more antihypertensive drugs

10. Patients are positive of urine protein (urine protein detection 2+ or above, or 24 hours urine protein quantitative >1.0g)

11. The patient currently has gastrointestinal diseases such as active gastric and duodenal ulcers, ulcerative colitis, or active bleeding from unresectosed tumors, or other conditions determined by researchers that may cause gastrointestinal bleeding or perforation

12. Patients with significant evidence or history of bleeding tendency within 3 months prior to enrollment (bleeding within 3 months >30 mL, hematemesis, black stool, blood in stool), hemoptysis (within 4 weeks >5 mL fresh blood) or a thromboembolic event (including stroke and/or transient ischemic attack) within 12 months

13. Cardiovascular disease of significant clinical significance, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure more than class II ; Ventricular arrhythmias requiring medical treatment; An electrocardiogram (ECG) showed a QT c interval =480 milliseconds

14. Active or uncontrolled severe infection (=CTCAE grade 2 infection)

15. A history of human immunodeficiency virus (HIV) infection or clinically significant liver disease, including viral hepatitis [active HBV infection must be ruled out as a known carrier of hepatitis B virus (HBV), i.e. positive HBV DNA (>1×104 copies /mL or >2000 IU/ml); known hepatitis C virus infection (HCV) and HCV RNA positive (>1×103 copies /mL), or other hepatitis, cirrhosis]

16. The researchers consider those who were not suitable for inclusion

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Envolimab
Envolizumab 300mg, D1, ih, Q3W 4-6cycles
• Fruquintinib
Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles
• Oxaliplatin
Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles
• Tegafur
Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time Q3W 4-6cycles

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Fujian Medical University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Surgical conversion rate	Defined as the proportion of patients who have undergone surgical resection after multidisciplinary assessment after completing 4-6 cycles of conversion therapy	2-3 months
Secondary	Pathological complete response (pCR)	Measured as the proportion of participants with a pathological complete response at the time of definitive surgery.	4 months
Secondary	Median disease free survival (DFS) time	The time from opreation to the time when only 50% of the individuals had no relapse or tumor progression	3 years
Secondary	1-year DFS rate		1 year
Secondary	3-year DFS rate		3 years
Secondary	Objective response rate (ORR)	Defined as the percentage of the participants in the analysis population who had a confirmed patial response and complete reponse according to RECIST 1.1 based on investigator assessment	4 months
Secondary	Major pathological response rate (MPR)	The proportion of participants with a major pathological response (mPR) at the time of definitive surgery.	4 months
Secondary	R0 resection rate	Defined as no residue under the microscope after resection	2-3 month
Secondary	Median survival time	The time from enrollment to the time when only 50% of the individuals alive	3 years
Secondary	Adverse event (AEs)	Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. The number of Participants with adverse events will be recorded at each treatment visit.	2 years
Secondary	Quality of life (QOL)	The quality of life of patients during treatment is eveluated by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (V3.0)	2 years